Oxford Nanopore signs CRISPR licence

UK-based Oxford N anopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Emotional Perception exclusive: ‘We are now very much open for business’

16 February 2026 Following the UK Supreme Court’s recent landmark judgment, which ushers in a sea-change to patent law, the team behind a groundbreaking AI-related invention sit down with Sarah Speight to explain how they got here, and why the ruling changes everything.

Europe

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

12 February 2026 The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.

Europe

Reaction: Emotional Perception decision is ‘good for UK PLC’

12 February 2026 UK and European patent attorneys share their initial views after the UK Supreme Court delivered its landmark judgment, which “brings some much‑needed clarity and consistency” to the patentability of AI-related innovations—including those in the medtech industry.

More features

Abbott unit defends European protection for heart valve ‘cuff’ design

Natera targets ex-employee over mass file download before rival move

Hogan Lovells makes senior public and administrative hire in Italy

Danaher moves to acquire Masimo in $9.9bn deal

Generic rival blocked as AZ defends diabetes stronghold

Emotional Perception exclusive: ‘We are now very much open for business’

New rankings recognise top US patent firms and lawyers

Norton Rose Fulbright expands pharma and biotech disputes team

Oxford Nanopore signs CRISPR licence

More on this story

Editor's picks

Editor's picks

More features